Effective November 28, 2023, Aeglea BioTherapeutics, Inc. will change its Nasdaq Capital Market stock ticker symbol to SYRE from AGLE.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37 USD | -2.58% | +5.32% | +71.93% |
May. 15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
May. 13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+71.93% | 1.93B | |
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Aeglea BioTherapeutics, Inc. will Change its Ticker to SYRE from AGLE